This suggests that in the treatment of gliomas, developing targeted inhibitors against SHP2 or employing a treatment regimen that combines SHP2 inhibitors with other signaling pathway inhibitors and traditional chemotherapeutic drugs, is expected to bring more effective treatment strategies for glioma patients. This evidence concerns the gene PTPN11 and central nervous system cancer.